<h2 id="Headline">
 Headline
</h2>
<h3 id="Swiss_Prot_in_the_sky_with_psilocybin__the_biosynthesis_pathway_of_a_psychedelic_drug_unveiled">
 Swiss-Prot in the sky with psilocybin: the biosynthesis pathway of a psychedelic drug unveiled
</h3>
<p>
 Psychedelic mushrooms, also called 'magic mushrooms', have been used by humans since prehistoric times and can be found depicted in Stone Age rock art in Europe and Africa. Some cultures have used them for religious rites and ceremonies, especially in pre-Columbian Mesoamerica. Aztecs and Mazatecs referred to them as genius mushrooms, divinatory mushrooms, and wondrous mushrooms. A Psilocybe species was known to the Aztecs as 'teōnanācatl', literally 'the divine mushroom'.
</p>
<p>
 The effects of many psychedelic mushrooms come from the pro-drug psilocybin. When psilocybin is ingested, this natural compound is rapidly metabolized to yield psilocin. This latter acts as a serotonergic psychedelic substance. Its effects include euphoria, altered thinking, visual hallucinations, altered sense of time and spiritual experiences. Some consider the drug as an
 <a href="https://en.wikipedia.org/wiki/Entheogen">
  entheogen
 </a>
 and a tool to supplement practices for transcendence. Psilocybin is considered to have low toxicity and harm potential, although some very rare cases of lethality have been reported. In most countries, psilocybin and psilocin are listed as schedule I drugs, i.e. compounds that have a high potential for abuse and are not recognized for medical use.
</p>
<p>
 Nevertheless, over the last 30 years, the potential medical and psychological therapeutic benefits of psilocybin have been investigated. Clinical studies revealed a positive trend in the treatment of existential anxiety with
 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20819978">
  advanced-stage cancer patients
 </a>
 and for
 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28019026">
  nicotine addiction
 </a>
 . Studies on the
 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28101325">
  clinical use of psilocybin against depression
 </a>
 are ongoing.
</p>
<p>
 The structures of both psilocybin and psilocin were determined in 1959 by
 <a href="http://onlinelibrary.wiley.com/doi/10.1002/hlca.19590420518/abstract">
  Hofmann et al.
 </a>
 , but the basis of their biosynthesis has remained obscure for almost 60 years. The locus for the biosynthesis of psilocybin, called psi,
 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28763571">
  has been recently identified
 </a>
 in 2 out of over 100 species of psilocybin mushrooms, namely
 <a href="http://www.uniprot.org/taxonomy/181762">
  <em>
   Psilocybe cubensis
  </em>
 </a>
 and
 <a href="http://www.uniprot.org/taxonomy/93625">
  <em>
   Psilocybe cyanescens
  </em>
 </a>
 .
</p>
<p>
 The psi locus encodes 4 psilocybin biosynthesis enzymes, including a new type of fungal L-tryptophan decarboxylase (
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPA6">
  psiD
 </a>
 ), a kinase (
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPA8">
  psiK
 </a>
 ), a methyltransferase (
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPA9">
  psiM
 </a>
 ), and a cytochrome P450 monooxygenase (
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPA7">
  psiH
 </a>
 ). All 4 have been characterized and are sufficient to produce psilocybin from the amino acid L-tryptophan. The first step of the psilocybin biosynthetic pathway is the decarboxylation of L-tryptophan to tryptamine by psiD. The cytochrome P450 monooxygenase psiH then converts tryptamine to 4-hydroxytryptamine. The kinase psiK catalyzes the 4-O-phosphorylation step by converting 4-hydroxytryptamine into norbaeocystin. The methyltransferase psiM eventually catalyzes iterative methyl transfer to the amino group of norbaeocystin to yield psilocybin via a monomethylated intermediate, called baeocystin. The psi locus also contains 2 major facilitator-type transporters (
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPB1">
  psiT1
 </a>
 and
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPB2">
  psiT2
 </a>
 ), as well as a cluster-specific transcriptional regulator (
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPB0">
  psiR
 </a>
 ).
</p>
<p>
 As of this release, expertly annotated
 <a href="http://www.uniprot.org/uniprot/?query=accession:P0DPA6+OR+accession:P0DPA7+OR+accession:P0DPA8+OR+accession:P0DPA9+OR+accession:P0DPB0+OR+accession:P0DPB1+OR+accession:P0DPB2">
  <em>
   Psilocybe cubensis
  </em>
  psi locus proteins psiD, psiH, psiK, psiM, psiR, psiT1, and psiT2
 </a>
 are publicly and legally available in UniProtKB/Swiss-Prot.
</p>
<h3 id="Changes_to_the__a_href___docs_humdisease__controlled_vocabulary_of_human_diseases__a_">
 Changes to the
 <a href="http://www.uniprot.org/docs/humdisease">
  controlled vocabulary of human diseases
 </a>
</h3>
<p>
 New diseases:
</p>
<ul>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05109">
   3-methylglutaconic aciduria 9
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05093">
   Al Kaissi syndrome
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05116">
   Auditory neuropathy and optic atrophy
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05103">
   Blepharocheilodontic syndrome 1
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05104">
   Blepharocheilodontic syndrome 2
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05097">
   Combined oxidative phosphorylation deficiency 32
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05115">
   Combined oxidative phosphorylation deficiency 33
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05089">
   Deafness, autosomal dominant, 73
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05082">
   Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05100">
   Encephalopathy, progressive, early-onset, with brain atrophy and spasticity
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05090">
   Epileptic encephalopathy, early infantile, 56
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05114">
   Epileptic encephalopathy, infantile or early childhood
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05118">
   Epiphyseal dysplasia, multiple, 7
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05120">
   Facial palsy, congenital, with ptosis and velopharyngeal dysfunction
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05098">
   Fraser syndrome 2
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05099">
   Fraser syndrome 3
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05105">
   Galloway-Mowat syndrome 2, X-linked
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05106">
   Galloway-Mowat syndrome 3
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05107">
   Galloway-Mowat syndrome 4
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05108">
   Galloway-Mowat syndrome 5
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05124">
   Hypertryptophanemia
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05121">
   Immunodeficiency, developmental delay, and hypohomocysteinemia
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05096">
   Joint laxity, short stature, and myopia
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05123">
   Microcephaly, seizures, spasticity, and brain calcifications
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05086">
   Myopathy, mitochondrial, and ataxia
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05101">
   Neurodegeneration, childhood-onset, with brain atrophy
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05113">
   Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05110">
   Neurodevelopmental disorder with microcephaly, ataxia, and seizures
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05119">
   Neuronopathy, distal hereditary motor, 9
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05111">
   Oocyte maturation defect 3
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05112">
   Oocyte maturation defect 4
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05092">
   Ovarian dysgenesis 5
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05102">
   Pilarowski-Bjornsson syndrome
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05088">
   Pituitary adenoma 3, multiple types
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05087">
   Pituitary adenoma 5, multiple types
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05117">
   Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05084">
   Pontocerebellar hypoplasia 11
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05083">
   Spermatogenic failure 22
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05085">
   Spermatogenic failure 23
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05091">
   Spinocerebellar ataxia 44
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05122">
   Sweeney-Cox syndrome
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05094">
   Vertebral, cardiac, renal, and limb defects syndrome 1
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/diseases/DI-05095">
   Vertebral, cardiac, renal, and limb defects syndrome 2
  </a>
 </li>
</ul>
<p>
 Modified diseases:
</p>
<ul>
 <li>
  ACTH-secreting pituitary adenoma -&gt;
  <a href="http://www.uniprot.org/diseases/DI-01168">
   Pituitary adenoma 4, ACTH-secreting
  </a>
 </li>
 <li>
  Early-onset myopathy with fatal cardiomyopathy -&gt;
  <a href="http://www.uniprot.org/diseases/DI-01514">
   Salih myopathy
  </a>
 </li>
 <li>
  Erythrokeratodermia variabilis -&gt;
  <a href="http://www.uniprot.org/diseases/DI-00483">
   Erythrokeratodermia variabilis et progressiva 1
  </a>
 </li>
 <li>
  Fraser syndrome -&gt;
  <a href="http://www.uniprot.org/diseases/DI-01627">
   Fraser syndrome 1
  </a>
 </li>
 <li>
  Mental retardation, autosomal dominant 6 -&gt;
  <a href="http://www.uniprot.org/diseases/DI-03128">
   Mental retardation, autosomal dominant 6, with or without seizures
  </a>
 </li>
 <li>
  Microphthalmia, syndromic, 14 -&gt;
  <a href="http://www.uniprot.org/diseases/DI-04146">
   Microphthalmia/coloboma and skeletal dysplasia syndrome
  </a>
 </li>
 <li>
  Noonan syndrome-like disorder with loose anagen hair -&gt;
  <a href="http://www.uniprot.org/diseases/DI-02076">
   Noonan syndrome-like disorder with loose anagen hair 1
  </a>
 </li>
 <li>
  Osteochondritis dissecans short stature and early-onset osteoarthritis -&gt;
  <a href="http://www.uniprot.org/diseases/DI-02814">
   Short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans
  </a>
 </li>
 <li>
  Otospondylomegaepiphyseal dysplasia -&gt;
  <a href="http://www.uniprot.org/diseases/DI-01254">
   Otospondylomegaepiphyseal dysplasia, autosomal recessive
  </a>
 </li>
 <li>
  Pituitary adenoma, growth hormone-secreting, 1 -&gt;
  <a href="http://www.uniprot.org/diseases/DI-01689">
   Pituitary adenoma 1, multiple types
  </a>
 </li>
 <li>
  Pituitary adenoma, growth hormone-secreting, 2 -&gt;
  <a href="http://www.uniprot.org/diseases/DI-04304">
   Pituitary adenoma 2, growth hormone-secreting
  </a>
 </li>
 <li>
  Stickler syndrome 3 -&gt;
  <a href="http://www.uniprot.org/diseases/DI-01093">
   Otospondylomegaepiphyseal dysplasia, autosomal dominant
  </a>
 </li>
 <li>
  X-linked immunodeficiency with hyper-IgM 1 -&gt;
  <a href="http://www.uniprot.org/diseases/DI-02449">
   Immunodeficiency with hyper-IgM, type 1
  </a>
 </li>
</ul>
<p>
 Deleted disease
</p>
<ul>
 <li>
  Weissenbacher-Zweymueller syndrome
 </li>
</ul>
<h3 id="Changes_in__a_href___docs_subcell__subcellular_location_controlled_vocabulary__a_">
 Changes in
 <a href="http://www.uniprot.org/docs/subcell">
  subcellular location controlled vocabulary
 </a>
</h3>
<p>
 New subcellular locations:
</p>
<ul>
 <li>
  <a href="http://www.uniprot.org/locations/SL-0495">
   Cytoplasmic ribonucleoprotein granule
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/locations/SL-0497">
   Nucleolus fibrillar center
  </a>
 </li>
 <li>
  <a href="http://www.uniprot.org/locations/SL-0496">
   Stress granule
  </a>
 </li>
</ul>
<h3 id="Changes_to__a_href___docs_keywlist__keywords__a_">
 Changes to
 <a href="http://www.uniprot.org/docs/keywlist">
  keywords
 </a>
</h3>
<p>
 New keyword:
</p>
<ul>
 <li>
  <a href="http://www.uniprot.org/keywords/KW-1277">
   Toxin-antitoxin system
  </a>
 </li>
</ul>